title: Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).
authors.forename: C
authors.initials: C
authors.lastname: Hirst
authors.forename: S
authors.initials: S
authors.lastname: Raasch
authors.forename: G
authors.initials: G
authors.lastname: Llewelyn
authors.forename: N
authors.initials: N
authors.lastname: Robertson
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D018501:Antirheumatic Agents; D016756:Immunoglobulins, Intravenous; D000074323:Alemtuzumab